Redeye leaves its comment on Pila Pharma following the announcement of its year-end report.
Redeye is encouraged by Egetis Therapeutic’s announcement earlier today, stating that the FDA has gr...
Redeye leaves a comment on the Q4 report Initiator Pharma released earlier this morning.
Redeye endorses ISAB signing a new contract worth approximately SEK 0.
Full fart framåt Senzime rapporterade nettoomsättning på 3,7 mkr i Q4'21 (3,5).
Marknaden fortsätter vara avvaktande Omsättningen för Q4 uppgick till 21,2 mkr (30,2 mkr) och Arcoma...
Starkt kvartal från egen produktion Arises nettoomsättning uppgick till 278 (130) mkr och EBIT till ...
Plexian publicerade igår den 17 februari sin bokslutskommuniké för år 2021.
Solteq's growth remained good in Q4, but investments impacted on profitability.
Redeye makes slight downward estimate adjustments following the Q4 report.
Redeye notes a couple of interesting points in the full year report, although the company announced ...
Två helägda projekt tar tydliga steg framåt. Positiva besked från Fas-1 studierna banar väg för att ...
Redeye revisits its valuation of early-stage biotech company Active after significant progress acros...
Redeye notes another record quarter for BONESUPPORT and is encouraged by the persistent sales growth...
Framtiden sårvård med stor marknad är på väg till kommersialiseringsfas.
Redeye comments on the Q4 report from Bioservo. In total, a report without any surprises in our view...
Redeye gives its initial take of Paynova’s fourth-quarter report of 2021, which was slightly above o...
Redeye comments on Imint's Q4 report, which showed all-time net revenues and stable profitability.
Redeye comments on the Q4 report, which offered few surprises.
Vaisala’s Q4 topline was in line with our expectations, but earnings fell short due to declined marg...
